title: Sorbitan ester niosomes for topical delivery of rofecoxib.
abstract: The aim of the present investigation is to encapsulate rofecoxib in niosomes and incorporate the prepared niosomes into dermal gel base for sustained therapeutic action. Niosomes were prepared by lipid film hydration technique and were analyzed for size, entrapment efficiency and drug retention capacity. Niosomal vesicles were then incorporated into blank carbopol gel to form niosomal gel. The in vitro permeation study across pig skin was performed using Keshary-Chien glass diffusion cell. The size and entrapment efficiency of the niosomal vesicles increased with gradual increase in HLB value of nonionic surfactants used. Maximum drug entrapment was observed with Span 20 with HLB value of 8.6 and drug leakage from vesicles was less at refrigerated condition than at the room temperature. Higher proportion of cholesterol made the niosomal formulation more stable with high drug retention properties. The niosomal gel showed a prolong drug release behavior compared to plain drug gel. Differential scanning calorimetric study of drug loaded gel and pig skin after permeation study confirmed inertness of carbopol gel base toward rofecoxib and absence of drug metabolism in the skin during permeation study, respectively. The niosomal formulations were successfully prepared by lipid film hydration technique using cholesterol and Span as nonionic surfactant. Presence of cholesterol made niosomes more stable with high drug entrapment efficiency and retention properties. The lower flux value of niosomal gel as compared to plain drug gel across pig skin assured the prolong drug release behavior with sustained action.
authors.affiliation: Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh 786 004, India. du_mkd@yahoo.co.in
authors.forename: Malay K
authors.initials: MK
authors.lastname: Das
authors.forename: Narahari N
authors.initials: NN
authors.lastname: Palei
mesh_terms: D000287:Administration, Topical; D000818:Animals; D002784:Cholesterol; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D005782:Gels; D006601:Hexoses; D066298:In Vitro Techniques; D007783:Lactones / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008081:Liposomes / Q000737:chemistry; D012867:Skin / Q000378:metabolism; D013450:Sulfones / Q000008:administration & dosage* / Q000493:pharmacokinetics; D034421:Sus scrofa
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D004337:Drug Carriers; D005782:Gels; D006601:Hexoses; D007783:Lactones; D008081:Liposomes; D013450:Sulfones; C116926:rofecoxib; D002784:Cholesterol